Executive Editor, RheumNow.com
Rheumatology
Dr. John J. Cush, MD
|
|
Give Review
John J. Cush, MD practices Rheumatology. He researched medicine at St. George's University School of Medicine. He over the years received 6 awards: "Regional Top Doctor", "Best Doctors in Dallas", "Intern of the Year", "Super Doctor", "Top MD" and "Fellow". John Cush is a published doctor and has 66 publications published. The lastest was: 'Inhibitors of tumor necrosis factor in rheumatoid arthritis: Will that dog hunt?'
Publications
- Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol.
- Proceedings from the ACR Reproductive Health Summit: The management of fertility, pregnancy and lactation in women with autoimmune and systemic inflammatory Diseases.
- Editorial: pregnancy and rheumatoid Arthritis - do not let the perfect become the enemy of the good.
- Autoinflammatory Syndromes.
- Tocilizumab as monotherapy or in combination with nonbiologic Disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study.
- A comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-TNF antibody, in phase 3 clinical trials.
- Malignancy risks with biologic therapies.
- Nonserious infections: should there be cause for serious concerns?
- Placebo-controlled trial of tofacitinib monotherapy in rheumatoid Arthritis.
- Proceedings of the 2011 Rheumatology Winter Clinical Symposia--Arthur Kavanaugh, MD and John J. Cush, MD (proceedings editors) [course directors: Arthur Kavanaugh, MD,...
- Shared experiences and best practices in the management of rheumatoid Arthritis and Crohn's disease.
- Iatrogenic rheumatic Syndromes in the elderly.
- Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoArthritis.
- Remodeling a rheumatology practice to facilitate early referral.
- Safety overview of new Disease-modifying antirheumatic drugs.
- Concomitant leflunomide therapy in patients with active rheumatoid Arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
- Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid Arthritis in immunosuppressive trials or being treated with biological agents.
- The safety and efficacy of leflunomide in combination with infliximab in rheumatoid Arthritis.
- Wegener''s granulomatosis presenting as lower Back pain with prostatitis and ureteral obstruction.
- Cost evaluation of novel therapeutics in rheumatoid Arthritis (CENTRA): a decision analysis model.
- Inhibitors of tumor necrosis factor in rheumatoid Arthritis: Will that dog hunt?
- Rotator cuff dysfunction in patients with rheumatoid Arthritis.
- Sustained durability and tolerability of etanercept in Ankylosing spondylitis for 96 weeks.
- Laboratory monitoring of biologic therapies.
- Biological drug use: US perspectives on indications and monitoring.
- An evidence-based medicine approach to the diagnosis and management of musculoskeletal complaints.
- Comparison of sulfasalazine and placebo in the treatment of reactive Arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study.
- Comparison of sulfasalazine and placebo in the treatment of psoriatic Arthritis. A Department of Veterans Affairs Cooperative Study.
- Comparison of sulfasalazine and placebo in the treatment of Ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study.
- A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid Arthritis. The Xoma RA Investigator Group.
- Biologic interventions in rheumatoid Arthritis.
- The effects of nonsteroidal antiinflammatory drug therapy in early rheumatoid Arthritis on serum levels of soluble interleukin 2 receptor, CD4, and CD8.
- Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid Arthritis.
- Treatment of acute gouty Arthritis with intramuscular ketorolac tromethamine.
- Elevated interleukin-10 levels in patients with rheumatoid Arthritis.
- Drug-induced lupus: clinical spectrum and pathogenesis.
- Adult-onset Still's Disease and inflammatory orbital pseudotumor.
- Adult-onset Still's Disease. Clinical course and outcome.
- Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid Arthritis.
- The role of cytokines in the pathogenesis of rheumatoid Arthritis.
- Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid Arthritis patients treated with nonsteroidal an...
- Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid Arthritis.
- Cellular basis for Rheumatoid inflammation.
- Identification of subsets of human T cells capable of enhanced transendothelial migration.
- The intrinsic migratory capacity of memory T cells contributes to their accumulation in Rheumatoid synovium.
- A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with Rheumatoid a...
- Early Arthritis clinic: a USA perspective.
- Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus.
- A phase I study of ethyl acetate extract of the chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid Arthritis.
- Consensus recommendations for the assessment and treatment of rheumatoid Arthritis.
- Rheumatoid synovial CD4+ T cells exhibit a reduced capacity to differentiate into IL-4-producing T-helper-2 effector cells.
- US consensus guidelines for the use of cyclosporin A in rheumatoid Arthritis.
- Rationale and risks of novel immunomodulatory therapies in rheumatoid Arthritis.
- Treatment of rheumatoid Arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week...
- Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid Arthritis failing MTX monotherapy: open-label extension of a randomized, dou...
- Recombinant human tumor necrosis factor receptor (etanercept) for treating Ankylosing spondylitis: a randomized, controlled trial.
- The efficacy of switching from etanercept to infliximab in patients with rheumatoid Arthritis.
- The evolving use of tumor necrosis factor inhibitors in rheumatoid Arthritis.
- Baseline factors that influence ASAS 20 response in patients with Ankylosing spondylitis treated with etanercept.
- Early Arthritis clinics: if you build it will they come?
- Acute polyArthritis.
- An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.
- Can tumor necrosis factor inhibitors be safely used in pregnancy?
- Unresolved issues in identifying and overcoming inadequate response in rheumatoid Arthritis: weighing the evidence.
- Early rheumatoid Arthritis -- is there a window of opportunity?
Schools
St George39s University
Coney Island Hospital
Coney Island Hosptial
The University Of Texas Southwestern Medical School
St Johns University
Procedures Preformed
- Joint Drainage
- Steroid Injection
Conditions Treated
- Ankylosing Spondylitis
- Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Arthritis
- Bursitis
- Calcium Pyrophosphate Dihydrate Deposition Background: yellow;'>Background: yellow;'>Background: yellow;'>Disease (CPPD)
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Assurant Health
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
- Best Doctors in Dallas
- Intern of the Year
- Super Doctor
- Top MD
- Fellow
Education
-
St. George's University School of Medicine
Hospital
-
Baylor University Medical Center
Drug Facts
| NPI NUMBER | 1265492680 | |
| NPPES Provider LastName | CUSH | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 752314395 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 3577.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 425.0 | |
| Percent Opioid Claims | 11.88 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265492680 |
| Last Name Of The Provider | CUSH |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Wassila Amari, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catalina Orozco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Virginia W. Reddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cristina G. Arriens, MD |
|
|
Dr. Jessica Procter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary C. Bergman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Imran Iqbal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Naiara M. Alvarez, MD |
|
|
Julia A. Dilliard |
|
|
Dr. Lige B. Rushing, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bonnie J. Lammers, MD
This Doctor is OpenDoctor Recommended.
|